Genomics as an Investment Theme
Genomics as an investment theme Costs of sequencing a human genome have fallen to less than $1,000 China leads the world in gene sequencing The...
314 Views
SillaJen - Pipeline Review & Valuation Study
I surely understand SillaJen, Inc. (0908477D KS) is a very speculative stock to invest right now. It has virtually no revenue. We still have to...
354 Views
Biosimilar Battlefield: U.S. Humira Pushed to 2023
We are updating our market model to reflect the patent litigation settlement between Amgen Inc (AMGN US) and Abbvie Inc (ABBV US) , the...
546 Views
Surveying The Biosimilar Battlefield
The biosimilar market has been of particular interest to us in light of the high expectations set for Samsung Biologics Co., Ltd (207940 KS) and...
704 Views
The Disconnect Is Growing
Celltrion Inc (068270 KS) 's Inflectra, a biosimilar to Johnson & Johnson (JNJ US) 's Remicade, had little impact on the critical U.S. market...
608 Views